Treatment of liver metastases, an update on the possibilities and results

European Journal of Cancer

Volumn 38, Issue 7, 2002, Pages 1023-1033

  Ruers, T ^a   Bleichrodt, R P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Resection; Treatment

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MELPHALAN; MITOMYCIN; OXALIPLATIN; TUMOR NECROSIS FACTOR;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER STATISTICS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DRUG ACTIVITY; HUMAN; LIVER METASTASIS; LIVER PERFUSION; LUNG METASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PORTAL VEIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY; RISK FACTOR; SURGICAL MORTALITY; ULTRASOUND;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; INTRAOPERATIVE CARE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PREOPERATIVE CARE; SURVIVAL ANALYSIS;

EID: 0036230263     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00059-X     Document Type: Article

References (106)

1. Netherlands Cancer Registry
2. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history
3. Metastases: Incidence, detection nd valuation without histologic confirmation
4. J Factors influencing the natural history of colorectal liver metastases
5. Surgical resection of colorectal carcinoma metastases to the liver. A pronostic scoring system to improve case selection, based on 1568 patients
6. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection
7. Resection of colorectal liver metastases
8. Liver resection for colorectal metastases
9. Long-term survival following resection of colorectal hepatic metastases
10. Hepatic resection for metastatic colorectal cancer results in cure for some patients
11. Resection of liver metastases from colorectal cancer: The real impact of the surgical margin
12. Resection of both hepatic and pulmonary metastases in patients with colorectal cancinoma
13. Resection of hepatic and pulmonary metastases from colorectal cancer
14. Surgery for colorectal cancer metastases to the liver: Optimising the results of treatment
15. Hepatic lymph node involvement in resected cases of liver metasases from colorectal cancer
16. Peri-operative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma
17. Results of extensive surgery for liver metastases in colorectal carcinoma
18. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases
19. Detection of hepatic metastases in patients with carcinoma: Comparative sensitivities of sonography, CT, and MR imaging
20. Computed tomography of the liver and biliary tract
21. Hepatic metastases
22. Accuracy of intra-operative ultrasonography in diagnosing liver metastases from colorectal cancer: Evaluation with post-operative follow-up results
23. Role of staging laparoscopy in the treatment of hepatic malignancy
24. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography
25. False positive CT portography: Correlation with pathologic findings
26. Magnetic resonance imaging
27. Evaluation of bening vs malignant hepatic lesions with positron emission tomography
28. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
29. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-deoxy-D-glucose in recurrent colorectal cancer
30. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
31. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
32. 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
33. A combined PET/CT scanner for clinical oncology
34. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
35. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrence in 80 patients
36. Hepatic resections for colorectal metastases in The Netherlands
37. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants
38. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors
39. Resection of liver metastases of colorectal carcinoma
40. A study of prognostic factors for hepatic resection for colorectal metastases
41. A collective review of the world literature on hepatic cryotherapy
42. Cryotherapy of the resection edge after liver resection for colorectal cancer metastases
43. Place of cryosurgery in the treatment of malignant liver tumors
44. Metastatic tumors of the liver
45. Repeated liver resection for recurrent liver cancer
46. Repeat hepatectomy for colorectal liver metastases
47. Multivariate analysis of a personel series of 247 consecutive patients with liver metastases from colorectal cancer. I Treatment by hepatic resection
48. Hepatic resection for metastases of the colon and rectum
49. A new technique for hepatic infusional chemotherapy
50. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence
51. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5- fluorouracil and folinic acid for liver metastases of colorectal cancer
52. Results of the Intergroup (Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG). Prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5 FU after hepatic resection for colorectal liver metastases
53. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
54. A 5-year study of cryosurgery in the treatment of liver tumors
55. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer
56. Treatment of colorectal liver metastases by cryotherapy
57. Cryosurgery for colorectal liver metastases
58. Cryosurgery for the treatment of colorectal liver metastases: Long term results
59. Cryoablation of unresectable malignant liver tumors
60. Cryosurgical ablation of hepatic tumors
61. Effect of hepatic artery chemotherapy on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy
62. Hepatic metastases: Percutaneous radio-frequency ablation with cooled tip electrodes
63. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm
64. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies
65. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications
66. Radiofrequency ablation of 100 hepatic metastases with a mean follow up of more than 1 year
67. Radiofrequency thermal ablation of hepatic metastases
68. Radiofrequency ablation of unresectable hepatic malignancies: Lessons learned
69. Thermal ablation of liver metastases. Current status and prospects
70. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
71. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
72. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
73. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy
74. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
75. Oxaliplatin, 5-Fluorouracil, and leucovorin for patients with liver only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study
76. Research into results of resection of hilar bile duct cancer
77. Atrophy of the liver after occlusion of the bile ducts or portal vein and compensatory hypertrophy of the unoccluded portion its clinical importance
78. Preoperative portal vein embolization for hepatocellular carcinoma
79. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization
80. Dynamics of normal and injured human liver regenerastion after hepatectomy as assesed on the basis of computed tomography and liver function
81. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report
82. Portal vein embolization: Rationale, technique and future prospects
83. Résultats carcinologiques à long terme des hépatectomies réalisées après embolisation portale sélective
84. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization
85. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumours
86. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
87. Biochemical modulation of fluorouracil-evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma
88. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
89. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma
90. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
91. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
92. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
93. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
94. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
95. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
96. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
97. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
98. A randomized study of intahepatic versus systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
99. A randomised trial of continous versus hepatic intra-arterial floxuridine in patients with colorectal metastases to the liver: The Nothern California Oncology Group trial
100. Hepatic arterial chemotherapy in metastatic colorectal patients
101. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer
102. Development of a technique for isolated perfusion of the liver
103. Isolated liver perfusion in advanced metastases of colorectal cancers
104. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver
105. Increased local cytostatic drug exposure by isolated hepatic perfusion: A phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver
106. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to the liver